Patents by Inventor Andras Heczey

Andras Heczey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAR NKTs Expressing Artificial Micro RNA-Embedded shRNA for Downregulation of MHC Class I & II Expression
    Publication number: 20220348930
    Abstract: The present disclosure provides methods and compositions related to Natural Killer T cells that are engineered to knock down the expression of one or more endogenous major histocompatibility complex (MHC) gene. The present disclosure also provides engineered CAR NKT cells that resist rejection by allogeneic immune cells both in vitro and in vivo.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: Baylor College of Medicine
    Inventors: Andras HECZEY, Bin LIU, Leonid METELITSA
  • TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS
    Publication number: 20210220403
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: October 15, 2020
    Publication date: July 22, 2021
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Daofeng Liu, Gianpietro Dotti, Andras Heczey
  • TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS
    Publication number: 20210106622
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. METELITSA, Daofeng Liu, Gianpietro Dotti, Andras Heczey
  • CAR T CELLS WITH ONE OR MORE INTERLEUKINS
    Publication number: 20210094994
    Abstract: Embodiments of the disclosure encompass methods and compositions related to targeting of tumor antigen-positive cells with therapy using cells that express a chimeric antigen receptor that targets the tumor antigen-positive cells in the presence of None or more interleukins that enhance efficacy of the tumor antigen-specific chimeric antigen receptors. In specific embodiments, the tumor antigen is glypican-3 and the one or more interleukins are EL-15 and EL-21.
    Type: Application
    Filed: April 29, 2019
    Publication date: April 1, 2021
    Inventors: Andras Heczey, Sai Batra, Purva Rathi
  • GLYPICAN-3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
    Publication number: 20170281683
    Abstract: Embodiments of the disclosure include methods and compositions related to immunotherapy that targets glypican-3. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor that targets glypican-3 are contemplated, and uses thereof. In particular embodiments, medical conditions that are associated with glypican-3 expression or an overexpression of glypican-3 are treated with GPC3 CARs.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 5, 2017
    Inventors: Andras Heczey, Stephen M. G. Gottschalk, Leonid S. Metelitsa, Gianpietro Dotti, Wenpeng Li
  • TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS
    Publication number: 20140255363
    Abstract: The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 11, 2014
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Leonid S. Metelitsa, Daofeng Liu, Gianpietro Dotti, Andras Heczey